Pacific Biosciences of California Inc. buy UBS Group AG
Start price
17.11.23
/
50%
€7.17
Target price
17.11.24
€9.20
Performance (%)
-78.73%
Price
22:26
€1.53
Summary
This prediction is currently active. Massive losses of -78.73% have been the result for the BUY prediction by UBS_Group_AG. This prediction currently runs until 17.11.24. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacific Biosciences of California Inc. | -27.283% | -27.283% |
iShares Core DAX® | -5.630% | -5.765% |
iShares Nasdaq 100 | -8.559% | -13.005% |
iShares Nikkei 225® | -9.576% | -9.058% |
iShares S&P 500 | -6.631% | -7.103% |
Comments by UBS_Group_AG for this prediction
In the thread Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, down previously from $13.00.
Ratings data for PACB provided by MarketBeat
Stopped prediction by UBS_Group_AG for Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€5.53
16.02.24
16.02.24
€11.13
16.02.25
16.02.25
-72.39%
22:26
22:26